Gland Pharma's stock experienced a rise of 2.07% in Tuesday's session, with the price reaching Rs 1,917.00. The stock is a constituent of the Nifty Midcap 150 index. This increase reflects a positive movement from its previous close, with trading activity observed around 11:24 am.
Regarding the company's financial performance, Gland Pharma has demonstrated consistent revenue generation over the recent quarters. The consolidated revenue for the quarter-ending June 2025 stood at Rs 1,505.62 Crore, up from Rs 1,424.91 Crore in March 2025. Net profit for the same period was Rs 215.48 Crore, compared to Rs 186.54 Crore in the previous quarter. The EPS stood at Rs 13.08 in June 2025, increasing from Rs 11.32 in March 2025.
Here's a summary of Gland Pharma's quarterly financial performance:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 1,401.71 Crore | Rs 1,405.83 Crore | Rs 1,384.05 Crore | Rs 1,424.91 Crore | Rs 1,505.62 Crore |
| Net Profit | Rs 143.76 Crore | Rs 163.53 Crore | Rs 204.69 Crore | Rs 186.54 Crore | Rs 215.48 Crore |
| EPS | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 |
The company's yearly financial performance also presents a detailed overview. In the year-ending 2025, the revenue was Rs 5,616.50 Crore. The net profit for the same year stood at Rs 698.53 Crore, and the EPS was Rs 42.40. The book value per share (BVPS) was Rs 555.40, and the return on equity (ROE) was 7.63% for the year-ending March 2025. The debt-to-equity ratio was 0.03.
Here's a summary of Gland Pharma's yearly financial performance:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 3,462.88 Crore | Rs 4,400.71 Crore | Rs 3,624.60 Crore | Rs 5,664.72 Crore | Rs 5,616.50 Crore |
| Net Profit | Rs 996.96 Crore | Rs 1,211.66 Crore | Rs 781.04 Crore | Rs 772.46 Crore | Rs 698.53 Crore |
| EPS | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 |
| BVPS | 360.86 | 435.64 | 483.23 | 529.65 | 555.40 |
| ROE | 16.88 | 16.92 | 9.81 | 8.85 | 7.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
Gland Pharma's standalone yearly income statement shows sales of Rs 4,116 Crore for March 2025, compared to Rs 4,400 Crore for March 2022. The net profit was Rs 1,089 Crore, compared to Rs 1,212 Crore for March 2022.
Gland Pharma's standalone quarterly income statement shows sales of Rs 1,038 Crore for June 2025, compared to Rs 1,012 Crore for June 2024. The net profit was Rs 269 Crore, compared to Rs 222 Crore for June 2024.
The cash flow statement indicates that the net cash flow from operating activities was Rs 1,073 Crore for March 2025, compared to Rs 604 Crore for March 2021.
The balance sheet shows that the total assets were Rs 10,421 Crore for March 2025, compared to Rs 6,496 Crore for March 2021.
Key financial ratios for Gland Pharma show a P/E ratio of 24.07 and a P/B ratio of 2.69 as of March 2025. The company's debt-to-equity ratio was 0.00 as of March 2025.
In corporate actions, Gland Pharma announced an investor meet intimation on September 8, 2025. Additionally, the company announced the appointment of Secretarial Auditors on August 28, 2025, and the reappointment of Mr. Essaji Goolam Vahanvati as an Independent Director on the same date. The company announced a final dividend of Rs 18 per share with an effective date of August 14, 2025.
Shares of Gland Pharma were trading positively, rising 2.07% to Rs 1,917.00 in Tuesday's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
